CorMedix Future Growth
Future criteria checks 5/6
CorMedix is forecast to grow earnings and revenue by 59.6% and 47.1% per annum respectively while EPS is expected to grow by 60.7% per annum.
Key information
59.6%
Earnings growth rate
60.7%
EPS growth rate
Pharmaceuticals earnings growth | 20.9% |
Revenue growth rate | 47.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 09 Apr 2024 |
Recent future growth updates
Recent updates
We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth
Apr 06We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
Nov 02Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Jul 31CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans
Feb 25FDA again rejects CorMedix's application for lead candidate DefenCath, shares sink ~60%
Aug 08Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Jul 16We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
Mar 01Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Sep 09CorMedix Inc.'s (NASDAQ:CRMD) Intrinsic Value Is Potentially 58% Above Its Share Price
Feb 11We're Hopeful That CorMedix (NYSEMKT:CRMD) Will Use Its Cash Wisely
Jan 04Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 162 | 85 | N/A | N/A | 2 |
12/31/2025 | 82 | 7 | -19 | -18 | 4 |
12/31/2024 | 25 | -45 | -49 | -49 | 4 |
12/31/2023 | N/A | -46 | -39 | -38 | N/A |
9/30/2023 | 0 | -40 | -34 | -34 | N/A |
6/30/2023 | 0 | -37 | -31 | -31 | N/A |
3/31/2023 | 0 | -33 | -28 | -28 | N/A |
12/31/2022 | 0 | -30 | -25 | -24 | N/A |
9/30/2022 | 0 | -29 | -25 | -24 | N/A |
6/30/2022 | 0 | -31 | -25 | -24 | N/A |
3/31/2022 | 0 | -28 | -23 | -21 | N/A |
12/31/2021 | 0 | -28 | -23 | -21 | N/A |
9/30/2021 | 0 | -27 | -22 | -21 | N/A |
6/30/2021 | 0 | -25 | -23 | -23 | N/A |
3/31/2021 | 0 | -24 | -21 | -21 | N/A |
12/31/2020 | 0 | -22 | -22 | -22 | N/A |
9/30/2020 | 0 | -21 | -20 | -20 | N/A |
6/30/2020 | 0 | -47 | -17 | -17 | N/A |
3/31/2020 | 0 | -44 | -16 | -16 | N/A |
12/31/2019 | 0 | -44 | -15 | -15 | N/A |
9/30/2019 | 0 | -36 | -18 | -18 | N/A |
6/30/2019 | 1 | -14 | -20 | -20 | N/A |
3/31/2019 | 1 | -22 | -24 | -24 | N/A |
12/31/2018 | 0 | -27 | -24 | -24 | N/A |
9/30/2018 | 0 | -39 | -24 | -24 | N/A |
6/30/2018 | 0 | -39 | -26 | -25 | N/A |
3/31/2018 | 0 | -36 | -29 | -29 | N/A |
12/31/2017 | 0 | -33 | -29 | -29 | N/A |
9/30/2017 | 0 | -29 | N/A | -28 | N/A |
6/30/2017 | 0 | -28 | N/A | -28 | N/A |
3/31/2017 | 0 | -28 | N/A | -24 | N/A |
12/31/2016 | 0 | -25 | N/A | -22 | N/A |
9/30/2016 | 0 | -22 | N/A | -19 | N/A |
6/30/2016 | 0 | -18 | N/A | -16 | N/A |
3/31/2016 | 0 | -17 | N/A | -16 | N/A |
12/31/2015 | 0 | -18 | N/A | -13 | N/A |
9/30/2015 | 0 | -17 | N/A | -10 | N/A |
6/30/2015 | 0 | -17 | N/A | -9 | N/A |
3/31/2015 | 0 | -9 | N/A | -7 | N/A |
12/31/2014 | 0 | -21 | N/A | -6 | N/A |
9/30/2014 | 0 | -22 | N/A | -6 | N/A |
6/30/2014 | 0 | -19 | N/A | -5 | N/A |
3/31/2014 | 0 | -25 | N/A | -4 | N/A |
12/31/2013 | 0 | -10 | N/A | -4 | N/A |
9/30/2013 | N/A | -7 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRMD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: CRMD is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CRMD is expected to become profitable in the next 3 years.
Revenue vs Market: CRMD's revenue (47.1% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: CRMD's revenue (47.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CRMD's Return on Equity is forecast to be high in 3 years time